Ionis Pharmaceuticals, Inc.
IONS
Rank in Stocks
#2670
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Share Price
$42.95
Last synced: 2026-10-16
Market Cap
$7.14B
Change (1 day)
-2.65%
Change (1 year)
-41.23%
Country
US
Trade Ionis Pharmaceuticals, Inc. (IONS)
Category
Healthcare
EPS for Ionis Pharmaceuticals, Inc. (IONS)
EPS as of June 2026 TTM: $-3.46
According to Ionis Pharmaceuticals, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-3.46. At the end of 2023 the company had a EPS of $-2.56 an increase over its 2022 EPS that were of $-1.90.
EPS history for Ionis Pharmaceuticals, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.46 | 13.82% |
| 2024 | $-3.04 | 18.75% |
| 2023 | $-2.56 | 34.74% |
| 2022 | $-1.90 | 850.00% |
| 2021 | $-0.20 | -93.71% |
| 2020 | $-3.18 | -251.43% |
| 2019 | $2.10 | 1.45% |
| 2018 | $2.07 | -4,403.53% |
| 2017 | $-0.05 | -93.32% |
| 2016 | $-0.72 | -2.70% |
| 2015 | $-0.74 | 124.24% |
| 2014 | $-0.33 | -40.00% |
| 2013 | $-0.55 | -15.38% |
| 2012 | $-0.65 | -23.53% |
| 2011 | $-0.85 | 37.10% |
| 2010 | $-0.62 | -139.24% |
| 2009 | $1.58 | -1,315.38% |
| 2008 | $-0.13 | 0.00% |
| 2007 | $-0.13 | -79.03% |
| 2006 | $-0.62 | -46.09% |
| 2005 | $-1.15 | -54.37% |
| 2004 | $-2.52 | 47.37% |
| 2003 | $-1.71 | 28.57% |
| 2002 | $-1.33 | -20.36% |
| 2001 | $-1.67 | 15.97% |
| 2000 | $-1.44 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -600.58% |
US
|
|
| $-7.98 | 130.64% |
US
|
|
| $-5.29 | 52.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -901.73% |
NL
|
